Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ice treatment for kidney cancer shows promise in latest trial

NCT ID NCT02399124

Disease control Sponsor: IceCure Medical Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device called PROSENSE™ that freezes kidney tumors to destroy them. It involves 120 adults with small kidney cancers (up to 5 cm). The goal is to see if the freezing completely covers the tumor and prevents it from coming back over 5 years. The approach is minimally invasive and aims to control the disease without major surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cryotherapy (freezing) using the PROSENSE™ device
What this could lead to
If successful, this could provide a minimally invasive option to control kidney cancer without surgery, potentially reducing recurrence.
What could go wrong
This is a post-market data collection study, not a randomized trial, so results may not prove superiority over standard treatments. Risks include incomplete tumor freezing or complications like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2014

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient is above 18 years old. 2. The patient has enhanced solid mass of renal origin located in the kidney or elsewhere proved by imaging. 3. Patient's mass size is up to 5 cm at its largest dimension. 4. Patient is able to visit the clinic as needed during the 60-month follow-up period following the cryoablation procedure. 5. The patient has been informed of the study and agrees to its provisions, and has signed an IRB approved written informed consent, including data privacy authorization. Exclusion Criteria: 1. Patients with permanent coagulation disorders or severe medical instability or active infection. 2. Patients with any terminal illness. 3. Patient participating in other trials using drugs or devices.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Renal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Renal cell carcinoma

Contacts and locations

Locations

  • Bnei Zion Medical Center

    Haifa, Israel

  • Shamir Medical Center

    Ẕerifin, 70300, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.